BioAlliance Pharma receives €6.4 million in funding

for the development of its innovative cancer therapeutics

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment
of opportunistic infections in cancer and AIDS, today announced the award of €6.4 million in funding from OSEO
(the French state innovation agency). The company will devote the funds to the development of its novel
therapeutic entities for the treatment of invasive cancers.
The funding has been awarded to the “Cancer Anti-invasive Program” (CAP) private-public
consortium as part of OSEO’s Strategic Industrial Innovation scheme. The consortium (led by
BioAlliance Pharma) comprises two innovative SMEs (Oroxcell and Xentech), two mid-sized
companies (Novasep and CIT) – all of which will make project investments – and two
academic centers of excellence (the Ecole Normale Supérieure de Cachan and the Institut
Gustave Roussy de Cancérologie). The consortium’s total budget over 5 years is €9.9
million, including a number of grants-in-aid and repayable advances.
The collaborative program will enable the development of two very innovative therapeutic
products up to the commercialization phase: AMEPTM (a biotherapy indicated in invasive
melanoma) and a first-in-class anticancer drug that targets invasive cancers and makes
tumor cells revert to a normal phenotype.
In parallel, the consortium will develop innovative animal models of invasive cancers with
Xentech, highly predictive genotoxicity tests with Oroxcell and immunotoxicology tools with
CIT. Novasep will develop an R&D-phase pilot facility for generating highly potent active
ingredients (HPAIs). In collaboration with BioAlliance Pharma, the academic centers of
excellence will identify new markers for monitoring tumor invasion.
Dominique Costantini (BioAlliance Pharma’s President and CEO) emphasized: “This is a
significant amount of public funding and constitutes a major boost for the clinical
development of two of our high-added-value projects. All the consortium partners have
committed to infrastructure investments and the program will provide highly innovative
support for an industrial drug development pipeline”.

090316EN_OSEO ISI